Managing Systemic Light-Chain Amyloidosis

Publisher： Cambridge Scholars Publishing in association with GSE Research

ISSN： 1540-1405

Source： Journal of the National Comprehensive Cancer Network (JNCCN), Vol.5, Iss.2, 2007-02, pp. : 179-187

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Melphalan-based chemo regimens for light-chain amyloidosis

Inpharma, Vol. 1, Iss. 1606, 2007-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Amyloid Formation in Light Chain Amyloidosis

Current Topics in Medicinal Chemistry, Vol. 12, Iss. 22, 2012-11 ,pp. : 2523-2533

Bentham Science Publishers

Access to resources Recommend Favorite

Lenalidomide/melphalan/prednisone: Light-chain deposition disease leading to ischaemic cholangitis in an elderly patient with multiple myeloma: case report

Reactions Weekly, Vol. 1, Iss. 1241, 2009-01 ,pp. : 29-30

Adis International

Access to resources Recommend Favorite

RAGE a possible treatment target in systemic amyloidosis

Inpharma, Vol. 1, Iss. 1244, 2000-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Dialysis Anticoagulation Causing Postoperative Bleeding in a Patient with Systemic Amyloidosis

By Housel Joseph P. Zeitouni Nathalie C.

Dermatologic Surgery, Vol. 38, Iss. 9, 2012-09 ,pp. : 1557-1559

Elsevier

Access to resources Recommend Favorite